Urea

Urea

SCHEMBL7488270

COc1ccc(NC(=O)Nc2cccc([N+](=O)[O-])c2O)cc1.NC(N)=O

nearest known ligand 0.67

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR1 P25024 1/20 0.67
CXCR2 P25025 1/20 0.67
PKM P14618 3/20 0.56
MEN1 O00255 3/20 0.56
KMT2A Q03164 3/20 0.56
LMNA P02545 1/20 0.56
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
MAPT P10636 3/20 0.55
THRB P10828 1/20 0.55
RAB9A P51151 6/20 0.53
SMN1; SMN2 Q16637 6/20 0.53
NPC1 O15118 5/20 0.53
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
MAPK1 P28482 2/20 0.51
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7490526 0.96 CXCR1 (0.72) CXCR1CXCR2PKMMEN1KMT2A
SCHEMBL7486283 0.81 MEN1 (0.59) CXCR1CXCR2PKMMEN1KMT2A
SCHEMBL31061375 0.81 CXCR2 (1.00) CXCR1CXCR2MEN1KMT2ALMNA
SCHEMBL7491596 0.81 CXCR2 (1.00) CXCR1CXCR2MEN1KMT2ALMNA
SCHEMBL7493660 0.79 CXCR1 (0.67) CXCR1CXCR2MEN1KMT2ALMNA
SCHEMBL7488459 0.79 CXCR2 (0.85) CXCR1CXCR2PKMMEN1KMT2A
SCHEMBL7159826 0.78 MEN1 (0.60) PKMMEN1KMT2AMAPTRAB9A
Urea SCHEMBL7580884 0.75 CXCR1 (0.65) CXCR1CXCR2MEN1KMT2ALMNA
SCHEMBL7488276 0.75 MAPT (0.43) CXCR1CXCR2PKMMEN1KMT2A
SCHEMBL4128446 0.74 MEN1 (0.77) PKMMEN1KMT2ALMNACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0896531-A4 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORP (US) 2002-10-30 EP disclosed
US-20020128321-A1 IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION 2002-09-12 US disclosed
US-6262113-B1 HYDROXY- OR MERCAPTO-PHENYLUREAS SMITHKLINE BEECHAM CORPORATION 2001-07-17 US disclosed
US-6211373-B1 Phenyl urea antagonists of the IL-8 receptor SMITHKLINE BEECHAM CORPORATION 2001-04-03 US disclosed
EP-0896531-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1999-02-17 EP disclosed
US-5780483-A IL-8 receptor antagonists SMITHKLINE BEECHAM CORPORATION (US) 1998-07-14 US disclosed
WO-1997029743-A1 IL-8 RECEPTOR ANTAGONISTS SMITHKLINE BEECHAM CORPORATION (US) 1997-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128321-A1 IL-8 receptor antagonists CXCL8, CCR8, IL1RN CXCR1 21/4885CXCR2 15/4885PKM 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.